Kavita V Dharmarajan, MD Email Kavita Dharmarajan
- ASSOCIATE PROFESSOR | Radiation Oncology
- ASSOCIATE PROFESSOR | Geriatrics and Palliative Medicine
- Radiation Oncology
- Hospital Affiliation
- The Mount Sinai Hospital
- FPA/Radiation Ocology Associates 212-241-4855 212-241-4855
Kavita Dharmarajan, MD, MSc, is a board-certified radiation oncologist and Associate Professor of Radiation Oncology, Geriatrics, and Palliative Medicine at the Icahn School of Medicine at Mount Sinai. She also serves as Director of the Quality and Performance Improvement Committee in the Department of Radiation Oncology at Mount Sinai Hospital. Dr. Dharmarajan’s clinical work is focused on providing radiation treatment for metastatic cancers and multiple myeloma using a multidisciplinary, patient-centered approach. She has specialized expertise in advanced radiation techniques including stereotactic radiotherapy and hypofractionation, and she has worked extensively with vulnerable patient populations including those with multiply relapsed/refractory multiple myeloma, oligometastatic disease, and older adults. At Mount Sinai, she developed one of the first care delivery models in the nation to provide specialized multidisciplinary care for persons diagnosed with advanced or incurable cancers.
In addition to her clinical practice, Dr. Dharmarajan is an NIH-funded clinician-investigator and currently the principal investigator on a clinical study evaluating the trajectories of functional status over time among older adults who undergo radiation therapy as part of their cancer treatment. She has been co-principal investigator on numerous clinical studies combining radiation therapy and phase I-II anti-cancer agents including those that include the use of immunomodulatory drugs and biospecific agents in multiple myeloma and other cancers. Her work has been supported by the National Institute on Aging, the National Palliative Care Research Center, and the American Medical Association Foundation.
Dr. Dharmarajan has published over 60 original research articles, textbook chapters, and invited papers, and she has served on several national and international committees to promote the education and uptake of radiation therapy for treatment of metastatic disease and multiple myeloma. In recognition of her clinical excellence and innovation in research, she has been the recipient of the Association of Community Cancer Center’s Innovator Award and the American Geriatrics Society’s Silverstein Memorial Award.
BA, University of Texas at Austin
MSc, London School of Economics and Political Science
MD, Columbia University College of Physicians & Surgeons
Massachusetts General Hospital
Residency, Radiation Oncology
Memorial Sloan-Kettering Cancer Center
Paul B. Beeson Emerging Leaders Career Development Award in Aging
National Institute on Aging/National Institutes of Health
Jeffrey H. Silverstein Memorial Award
American Geriatrics Society
Butler Williams Scholar Program
National Institute on Aging
Association of Community Cancer Centers
Junior Faculty Career Development Award
National Palliative Care Research Center
Research Scholar Award
American Association of Hospice and Palliative Medicine
Resident Research Award
Radiological Society of North America
American Medical Association Foundation Seed Grant for Outstanding Young Investigators
American College of Radiation Oncology
Research and Education Foundation Award
American Association for Women Radiologists
Global Radiation Oncology Workforce Scholarship
American College of Radiation Oncology
Annual Meeting Scientific Abstract Award
American Society for Radiation Oncology
National Comprehensive Cancer Network Fellows’ Recognition Program
Quality of life in radiation patients with cancer
Desc: Dr. Dharmarajan is investigating the benefits and role of radiation therapy in achieving disease control as well as improving pain and other cancer-related symptoms among patients with cancer of any type, and in particular patients living with metastatic cancers or multiple myeloma.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Dharmarajan did not report having any of the following types of financial relationships with industry during 2021 and/or 2022: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.